IWC
BCAX

Integrated Wealth Concepts’s Bicara Therapeutics BCAX Stock Holding History

Integrated Wealth Concepts’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.84K Buy
+264
New +$5.89K ﹤0.01% 4711

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Integrated Wealth Concepts's BCAX Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 264 shares worth $7.84K. The stake represents ﹤0.01% of the portfolio and ranks #4711 among its holdings.

170 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Integrated Wealth Concepts held 264 shares of Bicara Therapeutics worth $7.84K as of Q2 2026.
  • Bicara Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #4711 holding.
  • 170 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.